September #63 : Dis-Advantage-S - by Rachel Lewis

POZ - Health, Life and HIV
Subscribe to:
POZ magazine
Join POZ: Facebook MySpace Twitter Pinterest
Tumblr Google+ Flickr MySpace
POZ Personals
Sign In / Join

Back to home » Archives » POZ Magazine issues

Table of Contents


Long Live The Queens

How To Vote

Pills! Chills! Thrills! Spills!

Keeping Up With The Jones

Alabama Bound

Green Alert!

Publisher’s Letter


Double Identity

Say What?

Thespian Avengers

Catching Up With...

Off-Line Service

Data Drill

Hair Comes The Condoms

There’s No Place Like Om

Straight To The Heart


Second Sex First


He’s All That

Recovery Lite

Road Trippin'

Beyond The Valley Of The Dolls

Change of Heart

Crossing the Liver

Warning: Natural Selection

Dandelion Whine

Teen Talk

Skin Deep

Resistance Assistance

Dishes On The Side

Kentucky Woman

Comfort Zone

The Funky Fungus Among Us

Most Popular Lessons

The HIV Life Cycle


Herpes Simplex Virus

Syphilis & Neurosyphilis

Treatments for Opportunistic Infections (OIs)

What is AIDS & HIV?

Hepatitis & HIV

email print

September 2000


by Rachel Lewis

It wasn’t until 100 women became infected with HIV that UNAIDS and Miami-based Columbia Laboratories decided it was time to end a study that, ironically, was looking at a possible way to block transmission. Researchers had hoped that Advantage-S, a topical gel that contains nonoxynol-9 and is currently sold as a spermicide, would stop HIV in its tracks. In the Phase III study, which involved 700 prostitutes and was conducted in South Africa, Thailand, Ivory Coast and Benin, women were given either Advantage-S or a placebo and, according to Columbia Labs, encouraged to use condoms. Researchers were shocked when those who received placebo—the vaginal cream Replens—showed a slightly lower rate of HIV transmission than those using Advantage-S.

The Advantage-S trial’s design raised ethical red flags for selecting possibly illiterate women from developing countries. “The reality is, if you are going to help these women, you have to conduct the tests on them,” William Bologna, Columbia’s chair and CEO, told The Wall Street Journal in June. “Mary Jane in Toledo, Ohio, is not at high risk for the transfer of HIV. It’s these poor women in Africa.”

The trial has also launched a legal battle. Columbia Labs’ shareholders filed a suit just days after the announcement, arguing that the company misled them when they released preliminary data from the trial that suggested promising results. So what’s next? According to Dominique De Santis, a UNAIDS spokesperson, the future of microbicides still looks bright: “There are other products out there that are in large-scale clinical trials. We must not give up hope.”

[Go to top]

Facebook Twitter Google+ MySpace YouTube Tumblr Flickr Instagram
Quick Links
Current Issue

HIV Testing
Safer Sex
Find a Date
Newly Diagnosed
HIV 101
Disclosing Your Status
Starting Treatment
Help Paying for Meds
Search for the Cure
POZ Stories
POZ Opinion
POZ Exclusives
Read the Blogs
Visit the Forums
Job Listings
Events Calendar
POZ on Twitter

Ask POZ Pharmacist

Talk to Us
Did you participate in an event for National Black HIV/AIDS Awareness Day 2016?


more surveys
Contact Us
We welcome your comments!
[ about Smart + Strong | about POZ | POZ advisory board | partner links | advertising policy | advertise/contact us | site map]
© 2016 Smart + Strong. All Rights Reserved. Terms of use and Your privacy.
Smart + Strong® is a registered trademark of CDM Publishing, LLC.